Clinical Application Value of Lactobacillus Plantarum PS128 in Patients with Anxiety Disorders
10.9758/cpn.2022.20.3.560
- Author:
Xiaojuan MENG
1
;
Yajie GAO
;
Hang QI
;
Yongyan DING
;
Yaqing SUN
Author Information
1. Departments of Psychiatry, The Eighth Hospital of Shijiazhuang, Hebei, China
- Publication Type:Original Article
- From:Clinical Psychopharmacology and Neuroscience
2022;20(3):560-566
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objective:PS128 is a novel psycho biotic strain, it has been reported to play an important role in neuropsychiatric disorders. This study investigated the clinical effect of PS128 supplementation on patients with anxiety.
Methods:A total of 200 patients with anxiety were recruited, and divided into two groups (n = 100/group). The control group received oral treatment with citalopram, and the PS128 group received PS128 capsules based on citalopram treatment. Hamilton Anxiety Scale (HAMA) and Self-Rating Anxiety Scale (SAS) were used to evaluate the anxiety levels.After 2 months of continuous administration, clinical efficacy was evaluated according to HAMA score.
Results:There was no significant difference in HAMA and SAS scores between the two groups before treatment. With the treatment prolonged, the HAMA and SAS score decreased gradually in both control and PS128 groups, and the decrease rate of PS128 group was significantly greater than that of the control group. The clinical effective rates of PS128 group were higher than those in the control group, high levels of clinical cure rate were also detected in the PS128 group. Compared with the control group (22%), the incidence of adverse reactions was significantly reduced for patients in the PS128 group (4%).
Conclusion:The treatment effect of citalopram combined with PS128 against anxiety is satisfactory clinically. It can greatly improve the anxiety symptoms of patients, increase the cure rate, reduce adverse reactions.
